XML 39 R27.htm IDEA: XBRL DOCUMENT
v3.10.0.1

Revenue (Tables) | 3 Months Ended
--- | ---
Sep. 30, 2018
Revenue From Contract With Customer [Abstract] |
Composition of Total Revenue by Product and U.S versus Rest of World | The following table presents detail regarding the composition of our total revenue by product and U.S versus rest of world, “RoW”:
|  | Three months ended September 30, |
|  | 2018 |  |  | 2017 |
(In millions) |  | U.S. |  |  | RoW |  |  | Total |  |  | U.S. |  |  | RoW |  |  | Total |
Molecular diagnostic revenues: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Hereditary Cancer Testing |  | $ | 113.5 |  |  | $ | 2.8 |  |  | $ | 116.3 |  |  | $ | 114.6 |  |  | $ | 2.4 |  |  | $ | 117.0 |
GeneSight |  |  | 29.3 |  |  |  |  |  |  |  | 29.3 |  |  |  | 28.8 |  |  |  |  |  |  |  | 28.8 |
Prenatal |  |  | 18.1 |  |  |  | — |  |  |  | 18.1 |  |  |  | — |  |  |  | — |  |  |  | — |
VectraDA |  |  | 13.0 |  |  |  | — |  |  |  | 13.0 |  |  |  | 14.0 |  |  |  | — |  |  |  | 14.0 |
Prolaris |  |  | 6.2 |  |  |  | — |  |  |  | 6.2 |  |  |  | 3.9 |  |  |  | — |  |  |  | 3.9 |
EndoPredict |  |  | 0.3 |  |  |  | 2.1 |  |  |  | 2.4 |  |  |  | 0.0 |  |  |  | 1.8 |  |  |  | 1.8 |
Other |  |  | 3.6 |  |  |  | 0.1 |  |  |  | 3.7 |  |  |  | 1.8 |  |  |  | 0.1 |  |  |  | 1.9 |
Total molecular diagnostic revenue |  |  | 184.0 |  |  |  | 5.0 |  |  |  | 189.0 |  |  |  | 163.1 |  |  |  | 4.3 |  |  |  | 167.4 |
Pharmaceutical and clinical service revenue |  |  | 7.6 |  |  |  | 5.7 |  |  |  | 13.3 |  |  |  | 6.3 |  |  |  | 5.1 |  |  |  | 11.4 |
Total revenue |  | $ | 191.6 |  |  | $ | 10.7 |  |  | $ | 202.3 |  |  | $ | 169.4 |  |  | $ | 9.4 |  |  | $ | 178.8 |
Reconciliation of Deferred Revenue Balances | A reconciliation of the beginning and ending balances of deferred revenue is shown in the table below:
|  | Three months ended |
|  | September 30, |
|  | 2018 |  |  | 2017 |
Deferred revenue - beginning balance |  | $ | 2.6 |  |  | $ | 2.6 |
Revenue recognized |  |  | (1.7 | ) |  |  | (5.9 | )
Prepayments |  |  | 1.6 |  |  |  | 6.2 |
Deferred revenue - Ending Balance |  | $ | 2.5 |  |  | $ | 2.9 |

X
- Definition Tabular disclosure of contract balances and changes in contract balances. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 10 -URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130551-203045 + Details
Name: | us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130545-203045 + Details
Name: | us-gaap_DisaggregationOfRevenueTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_RevenueFromContractWithCustomerAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration